文献速递免疫规划妇幼与学校卫生慢病防控与筛查

澳大利亚2010-2070年HPV疫苗接种与初次HPV筛查对癌前病变治疗率及不良妊娠结局的预测影响:在高收入、高疫苗接种覆盖率且采用HPV筛查国家的模型研究

Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.
PubMed 文献 · Vaccine · 2025-03-15

该模型研究评估澳大利亚HPV疫苗接种和HPV筛查对癌前病变治疗及未来早产和低出生体重儿的影响。预测在HPV9疫苗接种和持续5年一次筛查下,癌前病变治疗率2010-2070年间下降82%;相比无疫苗接种,HPV9可避免800388例治疗,并减少22441例早产和32011例低出生体重儿。结论认为HPV疫苗接种的获益超出HPV相关疾病预防。

要点

  • HPV9疫苗接种和持续5年一次筛查下,癌前病变治疗率2010-2070年预计下降82%。
  • 相比无疫苗接种,HPV9可避免800388例癌前病变治疗,其中80%归因于HPV16/18保护。
  • 疫苗对HPV16/18的保护减少22441例早产和32011例低出生体重儿。

核心结论

  • HPV疫苗接种规划获益超出HPV相关疾病预防,可减少早产和低出生体重儿,未来对HPV9队列采用一生两次筛查可进一步减少。

研究设计与样本

  • 采用HPV感染、自然史、宫颈筛查和癌前病变治疗模型,结合生育与产科结局蒙特卡洛模型,估算澳大利亚2010-2070年单胎妊娠女性的癌前病变治疗、早产和低出生体重儿发生率和数量。
  • 设置四种情景:当前HPV筛查和疫苗接种规划的基础情景;HPV9队列未来一生两次筛查;未引入HPV疫苗接种规划的反事实情景;HPV4从未被HPV9替换的反事实情景。

主要发现

  • 在HPV9疫苗接种和持续5年一次筛查下,癌前病变治疗率2010-2070年预计下降82%;HPV9队列改为一生两次筛查可额外下降42%。
  • 相比无疫苗接种,HPV9在2010-2070年预计避免800388例治疗,其中80%归因于疫苗对HPV16/18的保护。
  • 因疫苗对HPV16/18的保护,2010-2070年预计减少22441例早产和32011例低出生体重儿;因对HPV31/33/45/52/58的保护,进一步减少4359例早产和6298例低出生体重儿。
  • HPV9队列未来一生两次筛查可额外避免3174例早产和4621例低出生体重儿。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of cervical precancer may be associated with an increased risk of adverse pregnancy outcomes. Australia introduced routine quadrivalent HPV vaccination (HPV4) in 2007, switching to nonavalent vaccination (HPV9) in 2018, and 5-yearly HPV screening in December 2017. We estimated the impact of HPV vaccination and HPV screening on precancer treatments, and thus on future preterm births (PTBs) and low birth weight (LBW) infants. METHODS: Using a model of HPV infection, natural history, cervical screening and precancer treatment, coupled with a Monte-Carlo model of fertility and obstetric outcomes, we estimated rates and numbers of precancer cervical treatments, PTBs and LBW infants in women with singleton pregnancies in Australia from 2010 to 2070. These outcomes were estimated for four scenarios: i) a base scenario, assuming the current HPV screening and vaccination programs; and three alternative scenarios: ii) future twice-lifetime screening in cohorts offered HPV9; (iii) no HPV vaccination program introduced (counterfactual); and (iv) HPV4 was never replaced with HPV9 (counterfactual). RESULTS: Precancer treatment rates are predicted to decrease by 82 % between 2010 and 2070 in the context of HPV9 vaccination and ongoing 5-yearly screening, with an additional 42 % reduction by changing to twice-lifetime screening in HPV9 cohorts. An estimated 800,388 treatments would be averted over 2010-2070 by HPV9 compared to no vaccination, 80 % of these due to vaccine protection against HPV16/18. These treatment reductions will result in 22,441 (32,011) fewer PTBs (LBW infants) over 2010-2070 due to vaccine protection against HPV16/18, and a further 4359 (6298) due to vaccine protection against HPV31/33/45/52/58. An additional 3174 (4621) events would be averted with future twice-lifetime screening in HPV9 cohorts. CONCLUSION: This analysis demonstrates that the benefits of HPV vaccination programs extend beyond prevention of HPV-related disease. HPV vaccination will reduce PTBs and LBW infants, with a further reduction with future twice-lifetime screening for HPV9 cohorts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yuill S, Hall MT, Caruana M, et al. Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening. Vaccine. 2025. PMID: 40090212. doi:10.1016/j.vaccine.2025.126986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。